Tin tức & Cập nhật

The selective potent oral BTK inhibitor remibrutinib has shown favourable efficacy and safety in the treatment of patients with Sjögren’s syndrome, according to the results of a phase II trial.

Patients with axial spondyloarthritis (axSpA) who are in a low disease activity (LDA) state or in remission tend to experience residual disease, which occurs more frequently among female patients, reveals a recent study.

Exposure to Janus kinase (JAK) inhibitors potentially carries an increased likelihood of developing acne, according to a study.

New drug applications approved by US FDA as of 16-31 October 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

In a real-world study presented at IDWeek 2023, dalbavancin has been shown to be an effective treatment alternative for patients with invasive gram-positive infections.

New drug applications approved by US FDA as of 01-15 October 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.